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 Abstract 
Aims: We estimate the impact of existing high coverage needle and syringe provision (HCNSP, 
defined as obtaining more than one sterile needle and syringe per injection reported) and 
opioid substitution therapy (OST) on hepatitis C virus (HCV) transmission among people who 
inject drugs (PWID) in three United Kingdom (UK) settings. We determine required scale-up of 
interventions, including HCV treatment, needed to reach the World Health Organisation (WHO) 
target of reducing HCV incidence by 90% by 2030. 
 
Design HCV transmission modelling utilising UK empirical estimates for effect of OST and/or 
HCNSP on individual risk of HCV acquisition  
 
Setting Three UK cities with varying HCV antibody prevalence (Bristol 60%, Dundee 46%, 
Walsall 32%), OST (72-81%), and HCNSP coverage (28-56%). 
 
Measurements Relative change in new HCV infections over 2016-2030 if current interventions 
were stopped.  Scale-up of HCNSP, OST and HCV treatment required to achieve the WHO 
elimination target. 
 
Findings Removing HCNSP or OST would increase the number of new HCV infections over 
2016-2030 by 23-64% and 92-483%, respectively. Conversely, scaling-up these interventions to 
80% coverage could achieve a 29% or 49% reduction in Bristol and Walsall, respectively, 
whereas Dundee achieves a 90% decrease in incidence with current levels of intervention 
because of existing high levels of HCV treatment (47-58 treatments per 1000 PWID). If OST and 
HCNSP are scaled-up, Walsall and Bristol can achieve the same impact by treating 14 or 40 per 
1000 PWID annually, respectively (currently 1-3 and 6-12 treatments per 1000 PWID), while 18 
and 43 treatments per 1000 PWID would be required if OST and HCNSP are not scaled-up. 
 
Conclusions Current opioid substitution therapy and high coverage needle and syringe 
provision coverage is averting substantial Hepatitis C transmission in the United Kingdom. 
Maintaining this coverage while initiating current injectors on treatment can reduce incidence 
by 90% by 2030.  
  
Introduction 
Hepatitis C virus (HCV) is a major cause of morbidity worldwide(1).  Approximately 85% of HCV 
infections in the UK are acquired through injection drug use(2, 3), therefore prevention of HCV 
transmission among people who inject drugs (PWID) is crucial for reducing the HCV disease 
burden.   
 
Primary prevention interventions for HCV are opioid substitution therapy (OST) and needle and 
syringe programmes amongst PWID(4). OST and high coverage needle and syringe provision 
(HCNSP, defined as obtaining more than one sterile needle and syringe per injection) can reduce 
the risk of HCV acquisition by 40-80%(5-10).  Although low in many settings(11, 12), UK 
coverage levels for OST (70%) and HCNSP (48%) are high(2).  Further, the emergence of highly 
efficacious antiviral HCV drugs(13) has raised the possibility of scaling-up HCV treatment as a 
prevention strategy amongst PWID(14, 15). Consequently, the World Health Organisation 
(WHO) recently produced a global strategy for eliminating HCV(1).   
 
Modelling has suggested that OST and HCNSP has reduced HCV prevalence in the UK, but 
further scale-up will have limited impact(16), with HCV treatment being needed to markedly 
reduce HCV prevalence(15, 17, 18). However, no analyses have considered how the impact of 
OST or HCNSP may vary between regional settings, or what combined scale-up of HCV 
treatment with OST and HCNSP are required to achieve the WHO HCV-elimination targets.  
 
In this paper, a HCV transmission model incorporating improved empirical evidence for the 
effectiveness of harm reduction interventions is used to evaluate the impact of current levels of 
OST and HCNSP on cumulative number of incident HCV infections in three UK settings (Bristol, 
Dundee and Walsall), and the required scale-up of these interventions with HCV treatment to 
reach WHO’s targets of reducing HCV incidence by 90% by 2030(1).  
 
 
Methods 
 
Model Description and assumptions 
We developed a dynamic deterministic model of HCV transmission and disease progression 
among PWID, similar to other HCV transmission models(16, 17) using principles outlined by 
recent guidelines for HIV or economic infectious disease models(19, 20). The model simulates 
the movement of current PWID through different stages of injecting duration, intervention 
coverage, risk and HCV infection states, as shown in Figure 1. Further model details are in the 
supplementary materials. 
 
Stratifications by injecting duration are included to incorporate increased injecting cessation 
and HCV-acquisition risk among people recently initiated into injecting(5, 21, 22), with the 
chosen category in line with reporting from the unlinked anonymous monitoring (UAM) survey 
of PWID (23). PWID are also stratified into different intervention states that influence HCV 
transmission risk: no intervention, OST only, HCNSP only, or both. PWID enter the model as 
recent initiates with no intervention coverage. They transition through successive injecting 
duration categories with rates of injecting cessation and non-HCV related death. Due to a lack of 
data, we assumed recruitment and leaving rates onto and off OST and HCNSP were independent 
of the current intervention state; previous modelling suggests this should not affect our model 
projections(16). The model is further stratified by high and low HCV transmission risk, with a 
proportion starting injecting in the high-risk category(24) and PWID transitioning between 
these categories. PWID were defined as high-risk if they had been homeless in the last year 
and/or injected crack in last 4 weeks (low-risk otherwise), which was associated with increased 
HCV transmission risk(25).   
 
New initiates into injecting are initially susceptible to HCV, and become infected at a per-capita 
rate depending on their intervention state, injecting duration category, risk category, and 
prevalence of HCV infection in the population. Previous analyses suggest incorporating like-
with-like mixing (individuals with the same risk behaviour or characteristics being more likely 
to form injecting contacts with each other than with other individuals) will have little effect on 
our model projections(16), with data suggesting it only occurs weakly in Bristol(26), and so 
random mixing was assumed between all sub-groups.   
 
Once infected, some PWID spontaneously clear infection(27), with the remainder becoming 
chronically infected, which is life-long unless treated. Chronically infected PWID progress 
through disease states (Figure 1c) with HCV disease-related death occurring from the 
decompensated cirrhosis, hepatocellular carcinoma, liver transplant and post-liver transplant 
stages.  
 
HCV treatment is only allowed in the F0-F3 and compensated cirrhosis states as it was 
contraindicated for more severe liver disease for interferon-based therapy (28) and evidence is 
only now emerging of its benefits with new DAA therapies(29). An annual number of PWID are 
treated, with a proportion achieving a sustained virological response (SVR-effective cure) and 
the remainder returning to their prior infection category. Following successful treatment, no 
further disease progression occurs in the F0-F3 states(30, 31), but continued slower 
progression occurs among those with compensated cirrhosis(31, 32).  We allow re-infection of 
those who have attained SVR, and re-treatment of those who fail treatment or become re-
infected in line with current recommendations(13).  
 
[Figure 1 here] 
 
Model Parameterisation 
The model was parameterised for three UK settings: Bristol, Dundee and Walsall.  These sites 
were chosen because of the availability of survey data and to give a range of epidemic settings.  
The model parameters and uncertainty ranges are given in Table 1 and Table S1.  Effect 
estimates for how HCV transmission risk is modified by OST and/or HCNSP, or injecting 
duration were taken from a pooled analysis of UK and Australian data(25) and a Cochrane 
systematic review(10). Estimated leaving rates from the high-risk category (1.16 per year), OST 
(1.65 per year) or HCNSP (0.52 per year) came from two UK studies(24, 33). 
 
HCV treatment was initiated in 2009 at rates determined by local data, except for Walsall where 
Bristol treatment rates were used. Before 2015, UK-specific PWID SVR rates(34) for pegylated 
interferon (pegIFN) and ribavirin (RBV) were assumed, whereas post-2015 a weighted average 
of SVRs for genotypes 1 and 2/3(35, 36) for direct acting antiviral drugs was assumed.   
 
HCV disease progression rates were calculated from two meta-analyses(28, 37) (Table S1). Non-
HCV related death rates were derived from two UK studies(21, 38).   
 
[Table 1 here] 
 
Model Calibration and uncertainty 
The model was calibrated to temporal data on HCV prevalence, recent estimates of coverage of 
OST and HCNSP, proportion of PWID with high-risk attributes, population size estimates of 
PWID, and their distribution by injecting duration (Table 2 and S2)(23, 26, 39-46). Data on HCV 
incidence for Dundee and Bristol, and HCV prevalence after 2006 for Bristol and Walsall were 
used for model validation, with both extracted from routine surveys of PWID (Needle exchange 
surveillance initiative in Scotland (NESI)(46), Unlinked anonymous monitoring survey (UAM) in 
England and Wales(23), and two additional community surveys using respondent driven 
sampling from Bristol(26), see supplementary information for details of the surveys). 
 
[Table 2 here] 
 
A sequential Bayesian method was used to calibrate the model, each to get 1,000 model fits. 
Firstly, a demographic sub-model was fitted to data on the population size of PWID for each 
setting and their distribution by injecting duration, which was assumed to be stable in 
Dundee(46), but decreasing(39-41, 47) and aging(26, 43-45, 48) in Bristol and Walsall. 
Secondly, an intervention sub-model was fitted to changing trends in the coverage of OST and 
HCNSP from each setting(26, 43, 46, 48), with OST coverage increasing in each setting over 
recent years from  40 to 70-81%, and the proportion with HCNSP remaining stable in Bristol 
(ranging between 38-82%) and Walsall (ranging between 21-42%), but increasing in Dundee 
(up to 34-79%, see Table S2). Thirdly, a high/low-risk sub-model was fitted to setting-specific 
data on the trends in crack injecting and/or homelessness(46, 48), which has remained stable in 
Dundee (33% high-risk) and Walsall (52% high-risk) but increased in Bristol over recent years 
(88% high-risk in 2014).   
 
Lastly, the full model was calibrated to HCV prevalence data from each setting.  For each of the 
1,000 combined parameter sets from the previous calibration steps, the model’s infection rate 
was calibrated to an initial sampled prevalence estimate for each city (Bristol 2004, Walsall 
2006 and Dundee 2008; Table S2 and Figure S1), assuming a stable epidemic at that time. For 
Walsall and Bristol, this infection rate accurately captured the subsequent epidemic dynamics 
(Figure S1), whereas for Dundee a second infection rate (median 2.0-fold (95% credibility 
interval (95%CrI) 1.8-2.7-fold) greater than initial infection rate) was used to capture the HCV 
prevalence in 2014. Table S2 summarises the model parameters obtained through model-fitting 
and the supplementary materials includes further detail. 
 
Model Analyses 
The model estimated the impact of current coverage levels of OST, HCNSP and HCV treatment 
over 2016-30, by comparing the baseline model with a counterfactual where the effect of these 
interventions was removed from 2016. Impact was assessed in terms of the relative change in 
the cumulative number of incident infections over 2016-2030.   Results were obtained for each 
parameter set and given in terms of 95% Credible Intervals (supplementary information for 
details). 
 
We then estimated the impact to 2030 of scaling up both OST and HCNSP to 80% coverage. This 
maximum coverage was partially based on the fact that 85% of PWID inject opioids(48), and so 
would derive a benefit from OST, and that higher intervention coverage levels are likely 
unsustainable(16). Additionally, the HCNSP target of 80% coverage is a current target of needle 
and syringe providers (personal communication Rachel Ayres). Following this, we estimated 
what additional HCV treatment scale-up is needed to reduce HCV incidence by 90% by 2030.  
We also considered how these projections were modified if the heightened transmission risk 
associated with our high-risk categories were halved. 
 Uncertainty Analysis 
A linear regression analysis of covariance (ANCOVA) (49) was undertaken to determine which 
parameter uncertainties (exposure variables in the linear regression analysis) contributed most 
to variability in the percentage reduction in incident HCV infections over 15 years due to 
current levels of HCNSP or OST (outcome variable). The proportion of each model outcome’s 
sum-of-squares contributed by each parameter was calculated to estimate the importance of 
individual parameters to the overall uncertainty. 
 
 
Results 
 
Baseline epidemic projections  
The chronic HCV prevalence pre-2016 was projected to be stable in all three settings (Figure 2). 
Over 2016-30, HCV prevalence will decrease slightly in Bristol (by 5%) and Walsall (by 0.4%), 
but reduce markedly in Dundee (by 99%). These decreases are due to the current scale-up of 
new treatments from 2015, with heightened impact in Dundee due to treatment already being 
scaled up (47-58 per 1000 PWID).  The projected HCV incidence in 2014 varied between 
settings.  The highest incidence was in Dundee (7.7 per 100py, 95% Credible Interval (CrI) 4.0-
12.6) and Bristol (6.9 per 100py, 95%CrI 3.9-11.5), both lower but comparable to recent 
empirical estimates from these settings (Dundee: 14.3 per 100py, 95% Confidence Interval (CI) 
4.9-25.9 (46) and Bristol: 10.0 per 100py, 95%CI 9.7-14.0(26)). Incidence was 3.4 per 100py in 
Walsall (95%CrI 1.7-6.6), corresponding to the low prevalence in that setting. Incidence is 
expected to decrease slightly in Walsall (by 1%) and Bristol (by 11%) over 2016-2030, but will 
decrease by over 90% in Dundee (99.97%, 95% CrI 99.0-99.99). 
 
[Figure 2 here] 
 
Impact of existing interventions 
Figures 2 and 3 (and Table S3) show that, regardless of setting, removing HCNSP and/or OST 
would lead to a large increase in the number of incident infections and increased HCV 
prevalence and incidence by 2030.  Removing OST has greater impact than removing HCNSP 
with less impact being achieved from removing HCV treatment. This differential impact is due 
both to the differing coverage of these interventions and their relative effectiveness. For 
example, in Walsall the number of incident infections over 2016-2030 would increase by 23%, 
129% or 176% if HCNSP, OST or both interventions were removed, respectively, compared with 
3% if HCV treatment were removed.  In Dundee, a greater increase (380%) would result from 
removing treatment because of the higher treatment rate in that setting. 
 
[Figure 3 here] 
 
Impact of combined OST/NSP interventions and treatment scale-up on HCV incidence  
Through scaling-up HCNSP and OST to 80% coverage from the current levels, it is possible to 
reduce HCV incidence by 29%(95%CrI 4.7-58%) in Bristol, 100%(95%CrI 99-100%) in Dundee 
and 49%(95%CrI 1.2-77%) in Walsall by 2030 compared to 2015 levels (Figure S2). Greater 
impact is achieved in Dundee due to recent HCV treatment scale-up. In all settings, most impact 
(>80%) is achieved from scaling-up HCNSP due to its lower baseline coverage (28-56% 
depending on setting).  
 
With current levels of HCNSP and OST, the annual number of HCV treatments needed to reduce 
incidence by 90% by 2030 (WHO elimination target) is 43(95%CrI 26-61), 29(95%CrI 14-45) 
and 18(95%CrI 8-36) per 1000 PWID for Bristol, Dundee and Walsall, respectively (Figure 4).  
This would require considerable scale-up of treatment in Bristol (5-fold from 9 annual 
treatments per 1000 PWID) and Walsall (9-fold from 2 annual treatments per 1000 PWID), 
while treatment numbers could be reduced by 45%(95%CrI 11-63%) in Dundee and still 
achieve this target. 
 
Concurrent scale-up of HCNSP and OST to 80% coverage decreases the yearly treatments 
required to reach the WHO target (Figure 4); from 43 to 40 per 1000 PWID for Bristol, 29 to 22 
for Dundee, and 18 to 14 for Walsall.  If, additionally, the transmission risk associated with high-
risk injecting (homelessness and crack injecting) was also halved then the required number of 
treatments would reduce further by one-fifth (19-22% - see Figure 4) in each setting. In all 
scenarios, fewer treatments are always needed in Dundee than the current number of 
treatments (47-58 per 1000 PWID). 
 
[Figure 4 here]   
 
Uncertainty analysis 
Analyses of covariance (Figure S3) suggest that most of the variability in the effect of removing 
HCNSP on increasing the number of infections between 2016-2030 is due to uncertainty in the 
efficacy of HCNSP (accounting for 41%, 4% and 49% of variability in Bristol, Dundee and 
Walsall, respectively), the coverage of HCNSP in 2014 (32% of variation in Bristol, 39% in 
Walsall and <1% in Dundee), and HCV prevalence in 2014 (77% in Dundee, 0.1% in Bristol, 3% 
in Walsall).  Increasing effectiveness and coverage of HCNSP increases the impact of removing 
the intervention (Bristol and Walsall) and in Dundee the lower the 2014 HCV prevalence the 
greater the increase in infections (Figure S4). All other parameters and inputs had little effect. 
For the impact of removing OST (Figure S5), most variability is due to uncertainty in the efficacy 
of OST (45% in Bristol, 44% in Dundee and 38% in Walsall).   
 
 
Discussion 
 
Main Findings 
Current levels of HCNSP and OST in the UK are averting considerable HCV transmission, with 
their removal likely to double the number of new HCV infections occurring over the next 15 
years. If HCNSP and OST levels are maintained, only moderate rates of HCV treatment (18-43 
per 1000 PWID annually) are needed to reduce HCV incidence by 90% by 2030, so achieving the 
WHO elimination target. This scale up has already been achieved in Dundee. Although scaling up  
HCNSP and OST further (to 80% coverage) will reduce these treatment targets (by a fifth), their 
existing moderate coverage in the UK limits the additional impact they can have.  
 
Strengths and limitations 
Our detailed modelling of three contrasting settings provides insights into how the impact of 
existing interventions varies across the UK, with our projections being strengthened by using 
detailed local data and utilising new synthesised estimates for the efficacy of OST and HCNSP. 
Additionally, calibrating our model to temporal trends in injecting duration and PWID 
population size allowed us to incorporate possible changes in injecting over recent years, 
increasing the potential realism of our model projections.   
 
However, limitations exist, primarily relating to the data used to inform our model. First, despite 
synthesising the best available international evidence(10), there remains substantial 
uncertainty in the intervention effectiveness of HCNSP, which our uncertainty analyses show 
was the most important contributor to uncertainty in our model projections. Further data 
collection of individual injecting frequency, real-life syringe provision and blood borne virus 
status could improve these estimates.  
 
Second, self-reported data on NSP coverage derived from surveys recruiting from needle and 
syringe providers are likely to overestimate coverage in the population as a whole(46, 50), so 
instead we estimated the HCNSP coverage in each city as the ratio of the number of syringes 
distributed to the estimated total number of injections undertaken by PWID in that city.  
Unfortunately, this measure utilised three uncertain pieces of information (PWID population 
size, yearly injecting frequency and the number of new needles distributed), with the resulting 
uncertainty in HCNSP coverage contributing considerably to the variability in our projections.  
Less biased estimates of syringe coverage could only come from better monitoring of service 
users.  
 
Third, our use of homelessness or crack use as a marker of high transmission risk is incomplete 
because it does not explicitly incorporate differences in injecting risk. This was done because of 
the inherent difficulty in using data on specific injecting behaviours to reliably estimate the 
variability in transmission risk between different PWID, and so we used proxy markers that 
have been found to be related to increased transmission risk. Importantly, previous 
analyses(15, 16) suggest risk heterogeneity rarely plays an important role in determining the 
impact of HCV interventions and so this simplification should not have affected our projections. 
 
Fourth, we assumed all PWID were eligible for OST despite a growing proportion (3.9% in 2004 
and 12% in 2014) are injecting non-opioids(2), for which OST is not an appropriate treatment.  
Although this was partially accounted for by assuming the coverage of OST could not be greater 
than 80%, future analyses could improve on this by explicitly modelling non-opioid injecting 
PWID as a separate group where HCNSP would be the only harm reduction strategy available. 
This could mean that existing interventions would have less prevention benefit. 
 
Fifthly, we assumed that HCV treatment was not allowed for individuals with severe liver 
disease (decompensated cirrhosis and beyond) despite recent treatment guidelines allowing it 
(13). This assumption is unlikely to affect our impact projections because fewer than 7% of all 
chronically infected PWID have this level of liver disease.  
 
Lastly, we assumed that Walsall had the same low treatment rate among PWID as Bristol due to 
lack of data.  This will have had little impact on our results which show that treatment needs to 
be scaled-up substantially to have a large impact on HCV incidence.  In contrast, current 
treatment numbers in Dundee are very high (25% of infected per year from 2015), with our 
modelling suggesting they will achieve HCV elimination by 2030 if maintained at this high level. 
To determine if this may have affected our impact projections for OST and HCNSP, we 
undertook a scenario analysis (not shown) which halved treatment rates from 2016 and 
showed similar impacts for the same levels of HCNSP and OST coverage. 
 
Comparison with other studies 
Few model analyses have estimated the impact of HCNSP or OST on HCV transmission, with 
previous analyses either not using empirical intervention effect estimates(51) and/or not using 
detailed context-specific data to evaluate how impact may vary across settings(16, 17). This 
analysis is consistent with previous findings that HCNSP and OST can have substantial 
impact(16), with our analysis also highlighting how impact can vary depending on local-levels 
of intervention coverage and epidemic trends. Additionally, our analysis is the first to estimate 
the required scale-up of OST, HCNSP and HCV treatment needed to achieve WHO’s HCV-
elimination targets amongst PWID in a European setting, with previous analyses either 
considering their required scale-up in a rural U.S. setting(52), or just the treatment scale-up 
requirements in Australia(53). Without scale-up of OST and HCNSP, our analyses suggest 
similar treatment rates (43/1000 PWID annually) are needed in Bristol as for Australia 
(59/1000 PWID annually), which has a similar chronic prevalence of HCV, but much lower than 
in the rural U.S. setting (89/1000 PWID annually) due to the increasing HCV epidemic occurring 
there. However, further scale-up of OST and HCNSP results in lower treatment rates being 
needed in the UK (14-44/1000 PWID annually) than in Australia, although the reduction is 
smaller (20% decrease in treatment requirements) than for the rural U.S. (halves treatment 
requirements) due to the negligible current coverage of these interventions in the U.S. setting.  
 
Conclusions and Implications  
Our projections highlight the considerable impact that existing harm reduction interventions 
are having in high coverage settings, such as Europe and Australia, emphasising the need to 
maintain current coverage levels of these interventions, avoid reductions in prevention funding, 
or changes in drug treatment policy away from harm reduction towards abstinence.  There is 
also an urgent imperative to continue funding for NSPs, since changes in drug use favouring 
non-opioid use may reduce the impact of OST. 
 
Our projections suggest benefits could be achieved from scaling-up OST and HCNSP further, 
especially in lower coverage settings such as Walsall. This highlights the need to initiate 
strategies for increasing the coverage of OST and HCNSP in these and similar settings, which 
should be done in close consultation with service users. Evidence shows the benefits of 
extending opening hours(54), and promotion of secondary distribution via peers(55, 56) or 
vending machines for increasing coverage(57). Additionally, better monitoring at the local 
district level is needed to identify lower coverage settings.  
 
Although our analyses emphasised the importance of OST and HCNSP for reducing HCV 
transmission, a combined approach utilising HCV treatment is needed to reduce HCV incidence 
to low-levels, as advocated by WHO.  This scale-up will require policy driven expansion of case-
finding interventions in settings such as drug treatment centres and NSPs, as already 
undertaken in Dundee; emphasising their crucial role for any scaled-up HCV prevention 
response. Strategies also need to be developed to reduce the harms associated with structural 
factors, such as homelessness and incarceration, which modelling suggests could be heightening 
HCV transmission amongst PWID(25, 58, 59). Such a multi-pronged approach must be 
prioritised to achieve the HCV-elimination targets set by WHO(1).  
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Figure 1: Schematics of different model components.  
1a: Schematic of injecting duration and infection components of model.   
Susceptible individuals are free from disease and upon infection move to the chronically 
infected category.  Successfully treated individuals move back into the susceptible category. 
Injecting duration is modelled as three categories; recently initiated PWID (denoted Recent 
PWID, <3 years), non-recent PWID (>=3 and <10 years) and long term PWID (>=10 years), with 
PWID transitioning through these categories at rates τi, where i = 1,2 for recent and non-recent 
injectors respectively.  Injectors cease injecting (cessation or death) at rate μi where i = 1,2,3 
for recent (<3 years of injecting), non-recent (>=3 years and <10 years) and long-term injectors 
(>=10 years) respectively. 
1b: Schematic of intervention component of model.  It is assumed the recruitment rates 𝛽 and 𝜂 
are independent of the current intervention state.  OST, opioid substitution therapy; HCNSP, 
high coverage needle and syringe provision (defined as at least one clean needle for every 
injection). 
1c: Schematic of disease progression component of the model.  Each of the disease states is 
stratified by injecting duration 𝑛, risk category 𝑚, OST category 𝑖 and NSP category 𝑗.  
Progression through the disease states occurs at a rate determined by the current disease state, 
as are the disease related death rates.  Metavir states F0, F1 (mild HCV disease), F2, F3 
(moderate HCV disease), compensated cirrhosis (also denoted as metavir state F4), 
decompensated cirrhosis, hepatocellular carcinoma (HCC), liver transplant and post-liver 
transplant.  All states have a cessation rate from injecting and a non-disease related background 
death rate.  Infection can occur between all disease states but not shown for clarity.  
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Figure 2 Impact of each intervention scenario on HCV incidence and prevalence in Bristol (2a 
and 2b), Walsall (2c and 2d) and Dundee (2e and 2f).  Thick solid line is median baseline 
scenario, with shaded region the 95% credible intervals.  The black points with thin whiskers 
are the data points (with 95% CrI) that were not fit to, whereas the black points with thick 
whiskers are the data points used for model calibration. 
2a and 2b: Bristol Incidence and prevalence 
 
2c and 2d: Dundee Incidence and prevalence 
 
2e and 2f: Walsall Incidence and prevalence 
 
  
Figure 3: Relative increase in new HCV infections (2016-2030) resulting from removing 
existing coverage levels of NSP, OST, both NSP and OST, HCV treatment of PWID or all 
interventions in each city.  The box-plots signify the uncertainty (middle line is the median, the 
limits of the box are 25% and 75% percentiles and the whiskers 2.5% and 97.5% percentiles). 
 
 
 
 
Figure 4: Required annual number of HCV treatments per 1000 PWID needed to reduce 
incidence by 90%, with or without HCNSP and OST scaling up to 80% coverage.  The box-plots 
signify the uncertainty in the model projections (middle line is the median, the limits of the box 
are 25% and 75% percentiles and the whiskers 2.5% and 97.5% percentiles).  The dashed boxes 
show the uncertainty range in the current treatment rate per 1000 PWID in each setting. 
  
Table 1 Model Parameters 
Parameters Symbol Value/Range Reference 
Epidemiological and Demographic parameters 
Number of new injectors 
per year 
𝜃 Fitted to obtain population 
sizes 
Bristol (39, 41), Walsall (41) and 
unpublished estimates, Dundee (42).  
See Table S2 and supporting information 
Combined mortality and 
injecting cessation rates 
per year 
 𝑖  Fitted to obtain injecting 
duration profiles for each 
setting 
Lower bounds of 0.004 and 0.008 
chosen to ensure leaving rate greater 
than the death rate (38, 60). See Table 
S2 and supporting information 
Infection rate per year 𝜋 Fitted to obtain HCV 
prevalence for each setting 
See Table S2 and supporting information 
Proportion of new 
infections which 
spontaneously clear 
𝛿 Sampled from uniform 
distribution (0.22-0.29) 
(27) 
Annual leaving rate from 
high to low risk 
behaviour 
𝜁 Sampled range (0.6761-
1.617) 
Data from cohort study (24) found 
78/145 injectors no longer homeless 
after 8 months. Transition probability 
sampled from beta distribution (α= 78 , 
𝛽 = 67) and converted to yearly rate 
Annual recruitment rate 
from low risk to high risk 
behaviour 
𝜎 Fitted to obtain required high 
risk proportions in each 
setting 
See Table S2 and supporting information 
Intervention Related parameters 
Annual OST leaving rate  𝛾 1-3 Duration on OST was 8 months (4-12 
months) in cohort of PWID in UK (60) 
Annual HCNSP leaving 
rate  
𝜅 0.37-0.77 Welsh cohort study 61% PWID still 
HCNSP after 1 year, so estimated 
duration on HCNSP as 1.3-2.7 years. (61) 
Annual recruitment rate 
into OST  
𝛽 Fitted to obtain required OST 
coverage proportions in each 
setting 
See Table S2 and supporting information 
Annual recruitment rate 
onto HCNSP  
𝜂 Fitted to obtain required high 
NSP coverage proportions in 
each setting 
See Table S2 and supporting information 
Proportion of treatments 
achieving SVR prior to 
2015 
𝛼 Sampled from uniform 
distribution (0.40-0.67)  
Weighted mean of pooled intention to 
treat SVR for genotypes 1 and 2/3 taken 
from UK treatment data for PWID (34) 
Proportion of treatments 
achieving SVR post 2015 
𝛼 Sampled from uniform 
distribution (0.86-0.92) 
(36) - Weighted mean of SVR for 
genotype 1 (90%) and genotypes 2/3 
(82-93%) from (35). 
Number of PWID treated 
per year 
Φ Bristol – 18 (2009 onwards) 
Dundee – 34 (2009 to 2015), 
and then 40 (2015 onwards) 
Walsall – 2 (2009 onwards) 
Number of HCV treatments in 2011.  
Assumed treatment of PWID 
commenced in 2009(34).  More recent 
estimate for Dundee (personal 
communication John Dillon).  Walsall 
assumed same rate as Bristol. 
Relative Transmission Risk parameters 
Risk associated with 
being on OST only 
Γ 0.41(0.22-0.75) sampled 
from Lognormal 
distribution 
Odds ratio and 95% CI from pooled 
analysis (25) 
Risk associated with 
being on HCNSP only 
Π 0.59(0.36-0.96) sampled 
from Lognormal 
distribution 
Odds ratio and 95% CI from pooled 
analysis (25) 
OST=Opioid Substitution Therapy, HCNSP=High Coverage Needle Syringe Provision, SVR= 
sustained virological response, high-risk defined as crack injecting in last 4 weeks or homeless 
in the last year. 
 
 
 
 
 
Table 2 Summary of baseline characteristics of people who inject drugs for each setting 
(minimum-maximum values)  
Baseline Characteristics 
(2014 unless stated) 
Setting 
Bristol Dundee Walsall 
Chonic HCV Prevalence  40-50% + 19-32% # 11-26% + 
HCV Incidence 10.0 per 100py, 95%CI 
9.7-14.0(26) in 2009 
14.3 per 100py, 95% CI 
4.9-25.9(46) 
Not available 
Population size (2011) 2025-2564 (62) 675-825 (42) 1296-1623 unpublished 
estimates 
Proportion High risk 80-95%+ 26-42% # 50-65% + 
Proportion on OST 77-86% (26) 65-79% # 61-82% + 
Proportion with HCNSP 38-82% +(39) 34-79% # 21-42% + 
Treatments per year 18 (34) 40 (from 2015) (personal 
communication John 
Dillon) 
2 (assumed similar rate 
per infected PWID as 
Bristol) 
+ Data extracted from unlinked anonymous monitoring survey (50), # data extracted from 
Needle Exchange Surveillance Initiative (46). OST=Opioid Substitution Therapy, HCNSP=High 
Coverage Needle Syringe Provision, high-risk defined as crack injecting in last 4 weeks or 
homeless in the last year, CI=confidence interval. 
 
 
 
 
 
 
 
 
Risk associated with 
being on both OST and 
HCNSP 
Γ × Π 0.26 (0.09-0.64)  Calculated as product of risk associated 
with being solely on OST or NSP. 
Compares well to estimate from 
systematic review 0.29 (0.13-0.65)(25) 
Risk associated with 
being a recent injector 
compared to a long-term 
injector 
Χ  1.53(0.93-2.52) sampled 
from Lognormal 
distribution 
Odds ratio from pooled analysis (25) 
Risk associated with 
being in the high-risk 
category 
Ξ Scotland: 2.13(1.40-3.24) 
Bristol and Walsall:  
2.75(1.97-4.22). Both 
sampled from lognormal 
distribution 
Odds ratio from pooled analysis (25). 
For Scotland, the OR is just for 
homelessness because there is little 
crack injection, whereas it is for crack 
injection or homelessness for Bristol and 
Walsall 
